Cost-effectiveness of nirmatrelvir/ritonavir in COVID-19 patient groups at high risk for progression to severe COVID-19 in the Netherlands.

ABSTRACT:

Background

Nirmatrelvir/ritonavir is indicated for the treatment of COVID-19 in symptomatic adults with increased risk for severe illness, not requiring supplemental oxygen yet. From a Dutch societal perspective, a cost-utility assessment of nirmatrelvir/ritonavir versus best supportive care (BSC) was conducted in three patient groups: (a) immunocompromised patients, (b) patients aged at least 60 years with one comorbidity, (c) patients aged at least 70 years. Groups were selected considering their relevance as high-risk groups, as described in Dutch and international guidelines and recommendations.

Methods

A one-year decision-tree, estimating costs and outcomes associated with a COVID-19 infection was coupled to a lifetime two-state Markov component simulating subsequent li

SUBMITTER: Arteaga Duarte CH 

PROVIDER: S-EPMC11852545 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature